Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2013

Yanagisawa Satoru, Inoue Akira, Koarai Akira, Ono Manabu, Tamai Tokiwa, Ichinose Masakazu

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Crizotinib
Share to Lung Diseases, Interstitial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oncogene Proteins, Fusion

Share to Pyrazoles

Share to Pyridines

Share to Retreatment

Source

Identifiers

PMID: 23857405
DOI: 10.1097/JTO.0b013e318293dfc1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.PMID 23857405Read ↗

Incorporation of crizotinib into the NCCN guidelines.Semantic proximity Read ↗

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.Semantic proximity Read ↗

Retreatment With Osimertinib Following Pneumonitis.Semantic proximity Read ↗

Resistance: Crizotinib makes a comeback.Semantic proximity Read ↗

Lung cancer. Dacomitinib: getting on target after negative ARCHER trial.Semantic proximity Read ↗

Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).Semantic proximity Read ↗

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.Semantic proximity Read ↗

Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.Semantic proximity Read ↗

Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.Semantic proximity Read ↗

Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease.Semantic proximity Read ↗

Dacomitinib-induced purpuric drug eruptions associated with IQGAP1 upregulation in a patient with lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.